We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+22.62%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$369M
AUM Growth
-$31.1M
Cap. Flow
-$8.88M
Cap. Flow %
-2.41%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$42.1B
$141M 38.24%
5,524,031
– –
FULC icon
2
Fulcrum Therapeutics
FULC
$288M
$93.7M 25.43%
3,962,202
– –
VYGR icon
3
Voyager Therapeutics
VYGR
$189M
$48.7M 13.21%
6,391,176
– –
PLRX icon
4
Pliant Therapeutics
PLRX
$65M
$40.9M 11.11%
5,839,160
– –
NRIX icon
5
Nurix Therapeutics
NRIX
$2.62B
$26.9M 7.31%
1,922,549
-500,000
-21% -$8.88M
DBTX
6
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$9.54M 2.59%
3,139,685
– –
JNCE
7
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$7.8M 2.12%
1,148,780
– –

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q1 2022 Portfolio in Review

As of Q1 2022, TRV GP III held 7 positions worth $369M, down 7.8% from $400M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 0%. TRV GP III opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q1 2022 reduction was Nurix Therapeutics, cutting an estimated $8.88M.
  • TRV GP III's ten largest holdings make up 100% of its $369M portfolio in Q1 2022.
  • TRV GP III opened 0 new positions and closed 0 in Q1 2022.
  • TRV GP III's portfolio value fell 7.8% quarter-over-quarter to $369M.

Based on TRV GP III's 13F filing for Q1 2022, filed 10 May 2022.